Singapore markets open in 7 hours 46 minutes

Lyell Immunopharma, Inc. (LYEL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.8150-0.0350 (-1.23%)
As of 12:12PM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 717.83M
Enterprise value 200.97M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)14.70
Price/book (mrq)1.03
Enterprise value/revenue 4.14
Enterprise value/EBITDA -1.10

Trading information

Stock price history

Beta (5Y monthly) -0.86
52-week change 318.75%
S&P500 52-week change 328.52%
52-week high 33.9700
52-week low 31.3200
50-day moving average 32.0376
200-day moving average 32.2487

Share statistics

Avg vol (3-month) 31.27M
Avg vol (10-day) 3965.19k
Shares outstanding 5251.87M
Implied shares outstanding 6251.87M
Float 8152.94M
% held by insiders 115.73%
% held by institutions 173.43%
Shares short (15 Feb 2024) 418.13M
Short ratio (15 Feb 2024) 420.79
Short % of float (15 Feb 2024) 410.29%
Short % of shares outstanding (15 Feb 2024) 47.20%
Shares short (prior month 12 Jan 2024) 415.62M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-236,156.01%

Management effectiveness

Return on assets (ttm)-14.19%
Return on equity (ttm)-25.05%

Income statement

Revenue (ttm)48.5M
Revenue per share (ttm)0.19
Quarterly revenue growth (yoy)733.30%
Gross profit (ttm)N/A
EBITDA -180.97M
Net income avi to common (ttm)-190.1M
Diluted EPS (ttm)-0.7600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)575.43M
Total cash per share (mrq)2.29
Total debt (mrq)64.64M
Total debt/equity (mrq)9.27%
Current ratio (mrq)16.74
Book value per share (mrq)2.80

Cash flow statement

Operating cash flow (ttm)-163.33M
Levered free cash flow (ttm)-74.96M